20 results on '"Balint JP Jr"'
Search Results
2. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
- Author
-
Gabitzsch ES, Tsang KY, Palena C, David JM, Fantini M, Kwilas A, Rice AE, Latchman Y, Hodge JW, Gulley JL, Madan RA, Heery CR, Balint JP Jr, Jones FR, and Schlom J
- Subjects
- Adenovirus E1 Proteins genetics, Adenovirus E1 Proteins immunology, Adenovirus E2 Proteins genetics, Adenovirus E2 Proteins immunology, Animals, Antigens, Neoplasm genetics, Carcinoembryonic Antigen genetics, Carcinoembryonic Antigen immunology, Dendritic Cells immunology, Female, Flow Cytometry, Genetic Vectors administration & dosage, Humans, Immunization, Interferon-gamma metabolism, Mice, Mice, Inbred C57BL, Neoplasms genetics, Neoplasms immunology, Neoplasms pathology, T-Lymphocytes immunology, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Adenoviridae genetics, Adenovirus Vaccines therapeutic use, Antigens, Neoplasm immunology, Cancer Vaccines therapeutic use, Immunotherapy, Neoplasms therapy
- Abstract
Phenotypic heterogeneity of human carcinoma lesions, including heterogeneity in expression of tumor-associated antigens (TAAs), is a well-established phenomenon. Carcinoembryonic antigen (CEA), MUC1, and brachyury are diverse TAAs, each of which is expressed on a wide range of human tumors. We have previously reported on a novel adenovirus serotype 5 (Ad5) vector gene delivery platform (Ad5 [E1-, E2b-]) in which regions of the early 1 (E1), early 2 (E2b), and early 3 (E3) genes have been deleted. The unique deletions in this platform result in a dramatic decrease in late gene expression, leading to a marked reduction in host immune response to the vector. Ad5 [E1-, E2b-]-CEA vaccine (ETBX-011) has been employed in clinical studies as an active vaccine to induce immune responses to CEA in metastatic colorectal cancer patients. We report here the development of novel recombinant Ad5 [E1-, E2b-]-brachyury and-MUC1 vaccine constructs, each capable of activating antigen-specific human T cells in vitro and inducing antigen-specific CD4+ and CD8+ T cells in vaccinated mice. We also describe the use of a combination of the three vaccines (designated Tri-Ad5) of Ad5 [E1-, E2b-]-CEA, Ad5 [E1-, E2b-]-brachyury and Ad5 [E1-, E2b-]-MUC1, and demonstrate that there is minimal to no "antigenic competition" in in vitro studies of human dendritic cells, or in murine vaccination studies. The studies reported herein support the rationale for the application of Tri-Ad5 as a therapeutic modality to induce immune responses to a diverse range of human TAAs for potential clinical studies.
- Published
- 2015
- Full Text
- View/download PDF
3. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.
- Author
-
Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM, Amalfitano A, Burnett BK, Devi GR, Hsu DS, Xu Y, Balcaitis S, Dua R, Nguyen S, Balint JP Jr, Jones FR, and Lyerly HK
- Subjects
- Adenoviridae genetics, Adenoviridae immunology, Adult, Aged, Antibodies, Neutralizing immunology, Cancer Vaccines administration & dosage, Cancer Vaccines genetics, Carcinoembryonic Antigen genetics, Cohort Studies, Colorectal Neoplasms therapy, Dose-Response Relationship, Drug, Enzyme-Linked Immunosorbent Assay, Female, Genetic Vectors genetics, Humans, Immunization methods, Interferon-gamma immunology, Interferon-gamma metabolism, Kaplan-Meier Estimate, Male, Middle Aged, T-Lymphocytes metabolism, Time Factors, Treatment Outcome, Cancer Vaccines immunology, Carcinoembryonic Antigen immunology, Colorectal Neoplasms immunology, Genetic Vectors immunology, T-Lymphocytes immunology
- Abstract
First-generation, E1-deleted adenovirus subtype 5 (Ad5)-based vectors, although promising platforms for use as cancer vaccines, are impeded in activity by naturally occurring or induced Ad-specific neutralizing antibodies. Ad5-based vectors with deletions of the E1 and the E2b regions (Ad5 [E1-, E2b-]), the latter encoding the DNA polymerase and the pre-terminal protein, by virtue of diminished late phase viral protein expression, were hypothesized to avoid immunological clearance and induce more potent immune responses against the encoded tumor antigen transgene in Ad-immune hosts. Indeed, multiple homologous immunizations with Ad5 [E1-, E2b-]-CEA(6D), encoding the tumor antigen carcinoembryonic antigen (CEA), induced CEA-specific cell-mediated immune (CMI) responses with antitumor activity in mice despite the presence of preexisting or induced Ad5-neutralizing antibody. In the present phase I/II study, cohorts of patients with advanced colorectal cancer were immunized with escalating doses of Ad5 [E1-, E2b-]-CEA(6D). CEA-specific CMI responses were observed despite the presence of preexisting Ad5 immunity in a majority (61.3 %) of patients. Importantly, there was minimal toxicity, and overall patient survival (48 % at 12 months) was similar regardless of preexisting Ad5 neutralizing antibody titers. The results demonstrate that, in cancer patients, the novel Ad5 [E1-, E2b-] gene delivery platform generates significant CMI responses to the tumor antigen CEA in the setting of both naturally acquired and immunization-induced Ad5-specific immunity.
- Published
- 2013
- Full Text
- View/download PDF
4. A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.
- Author
-
Wieking BG, Vermeer DW, Spanos WC, Lee KM, Vermeer P, Lee WT, Xu Y, Gabitzsch ES, Balcaitis S, Balint JP Jr, Jones FR, and Lee JH
- Subjects
- Adenocarcinoma metabolism, Adenoviridae genetics, Adenoviridae immunology, Animals, Cancer Vaccines genetics, Cell Line, Tumor, Head and Neck Neoplasms pathology, Humans, Male, Mice, Mice, Inbred C57BL, Mutagenesis, Site-Directed, Oncogene Proteins, Viral genetics, Papillomavirus E7 Proteins genetics, Papillomavirus Infections immunology, Papillomavirus Infections therapy, Papillomavirus Vaccines genetics, Repressor Proteins genetics, Adenocarcinoma therapy, Adenocarcinoma virology, Cancer Vaccines pharmacology, Head and Neck Neoplasms therapy, Head and Neck Neoplasms virology, Oncogene Proteins, Viral immunology, Papillomavirus E7 Proteins immunology, Papillomavirus Vaccines pharmacology, Repressor Proteins immunology
- Abstract
Human papillomaviruses (HPVs) are the causative factor for >90% of cervical cancers and 25% of head and neck cancers. The incidence of HPV positive (+) head and neck squamous cell carcinomas has greatly increased in the last 30 years. E6 and E7 are the two key viral oncoproteins that induce and propagate cellular transformation. An immune response generated during cisplatin/radiation therapy improves tumor clearance of HPV(+) cancers. Augmenting this induced response during therapy with an adenoviral HPV16 E6/E7 vaccine improves long-term survival in pre-clinical models. Here, we describe the generation of an HPV16 E6/E7 construct, which contains mutations that render E6/E7 non-oncogenic, while preserving antigenicity. These mutations do not allow E6/E7 to degrade p53, pRb, PTPN13, or activate telomerase. Non-oncogenic E6/E7 (E6(Δ)/E7(Δ)) expressed as a stable integrant, or in the [E1-, E2b-] adenovirus, lacks the ability to transform human cells while retaining the ability to induce an HPV-specific immune response. Moreover, E6(Δ)/E7(Δ) plus chemotherapy/radiation statistically enhances clearance of established HPV(+) cancer in vivo.
- Published
- 2012
- Full Text
- View/download PDF
5. Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.
- Author
-
Gabitzsch ES, Xu Y, Balint JP Jr, Balcaitis S, Sanders-Beer B, and Jones FR
- Subjects
- Animals, Female, Gene Deletion, Gene Products, gag genetics, Gene Products, gag immunology, Gene Products, nef genetics, Gene Products, nef immunology, Gene Products, pol genetics, Gene Products, pol immunology, Interferon-gamma metabolism, Lymphocytes immunology, Macaca mulatta, Male, SAIDS Vaccines administration & dosage, SAIDS Vaccines genetics, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic genetics, Vaccines, Synthetic immunology, Adenoviridae genetics, Adenoviridae immunology, Drug Carriers, Genetic Vectors, SAIDS Vaccines immunology
- Abstract
The effectiveness of recombinant Adenovirus serotype 5 (Ad5) vectors to induce immune responses against targeted antigens has been limited by the presence of pre-existing or Ad5 vaccine induced anti-vector immunity. The Ad5 [E1-, E2b-] platform, a recombinant Ad5 with additional deletions, has been previously reported by us to induce immune responses in the presence of Ad5 immunity. In an Ad5 immune non-human primate (NHP) model, an Ad5 [E1-, E2b-] construct expressing HIV-1 Gag induced immune responses in the presence of pre-existing Ad5 immunity. In the present study we expand on these prior observations by comparing the cell mediated immune (CMI) responses induced by Ad5 [E1-, E2b-]-SIV-gag/nef in Ad5 naïve and Ad5 immune NHP. Additionally, NHP were immunized with an Ad5 [E1-, E2b-]-HIV-pol construct following two homologous administrations of Ad5 [E1-, E2b-]-SIV-gag/nef to determine if an immune response could be induced against a third antigen in the presence of vaccine induced Ad5 immunity. Positive CMI responses, as assessed by interferon-gamma (IFN-γ) secreting lymphocytes, were induced against all three antigens. These CMI responses increased over a course of multiple immunizations and the response profiles observed in Ad5 naïve and Ad5 immune NHP were similar. No influence of the major histocompatibility complex on CMI responses was observed. These data indicate that the new Ad5 [E1-, E2b-] platform based vaccine could be used for homologous vaccination regimes to induce robust CMI responses in the presence of Ad5 vector immunity., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
6. An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice.
- Author
-
Gabitzsch ES, Xu Y, Balcaitis S, Balint JP Jr, and Jones FR
- Subjects
- Animals, Antigens, Neoplasm genetics, Blotting, Western, Breast Neoplasms immunology, Breast Neoplasms metabolism, Cell Line, Tumor, Cytotoxicity Tests, Immunologic, Enzyme-Linked Immunosorbent Assay, Enzyme-Linked Immunospot Assay, Female, Genetic Vectors genetics, Mice, Mice, Inbred BALB C, Neutralization Tests, Receptor, ErbB-2 genetics, Specific Pathogen-Free Organisms, Transgenes genetics, Adenoviridae, Antibodies, Neoplasm immunology, Antigens, Neoplasm immunology, Breast Neoplasms therapy, Genetic Vectors therapeutic use, Immunotherapy methods, Receptor, ErbB-2 immunology
- Abstract
Immunotherapy is a promising approach for the treatment of cancers. Modified adenovirus 5 (Ad5) vectors have been used as a platform to deliver genes encoding tumor associated antigens (TAA). A major obstacle to Ad5 vector immunotherapy has been the induction of vector immunity following administration or the presence of pre-existing Ad5 immunity, which results in vector mitigation. It has been reported by us that the Ad5[E1-, E2b-] platform with unique deletions in the E1, E2b and E3 regions can induce potent cell mediated immunity (CMI) against delivered transgene products in the presence of pre-existing Ad5 immunity. Here we report the use of an Ad5[E1-, E2b-] vector platform expressing the TAA HER2/neu as a breast cancer immunotherapeutic agent. Ad5[E1-, E2b-]-HER2/neu induced potent CMI against HER2/neu in Ad5 naïve and Ad5 immune mice. Humoral responses were also induced and antibodies could lyse HER2/neu expressing tumor cells in the presence of complement in vitro. Ad5[E1-, E2b-]-HER2/neu prevented establishment of HER2/neu-expressing tumors and significantly inhibited progression of established tumors in Ad5 naïve and Ad5 immune murine models. These data demonstrate that in vivo delivery of Ad5[E1-, E2b-]-HER2/neu can induce anti-TAA immunity and inhibit progression of HER2/neu expressing cancers., (© 2011 Nature America, Inc.)
- Published
- 2011
- Full Text
- View/download PDF
7. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.
- Author
-
Gabitzsch ES, Xu Y, Balint JP Jr, Hartman ZC, Lyerly HK, and Jones FR
- Subjects
- Adenoviridae immunology, Adenovirus E1 Proteins genetics, Adenovirus E2 Proteins genetics, Animals, Cancer Vaccines administration & dosage, Cancer Vaccines immunology, Carcinoembryonic Antigen genetics, Cell Line, Cell Line, Tumor, Gene Deletion, Genetic Vectors administration & dosage, Genetic Vectors genetics, Genetic Vectors immunology, Humans, Immunization methods, Mice, Mice, Inbred C57BL, Neoplasms, Experimental immunology, Neoplasms, Experimental pathology, Treatment Outcome, Adenoviridae genetics, Carcinoembryonic Antigen immunology, Immunotherapy methods, Neoplasms, Experimental therapy
- Abstract
Adenovirus serotype 5 (Ad5) has been widely used in clinical trials because it expresses inserted transgenes robustly and augments the innate immune response. Strategies to improve Ad5 vectors that can circumvent Ad5 immunity have become a critical issue, especially for use as a cancer immunotherapeutic in which repeated immunization is required. In this study, we constructed a novel Ad5 vector with unique deletions of the viral DNA polymerase and the pre-terminal protein region (Ad5 [E1-, E2b-]). This vector contains the carcinoembryonic antigen (CEA) gene insert and is designed to induce cell-mediated immunity (CMI) against the tumor-associated target. The CEA immunogenicity and in vivo anti-tumor effects of repeated immunizations with Ad5 [E1-, E2b-]-CEA compared with those observed with current generation Ad5 [E1-]-CEA were tested in Ad5 pre-immunized mice. We report that Ad5-immune mice immunized multiple times with Ad5 [E1-, E2b-]-CEA induced CEA-specific CMI responses that were significantly increased over those detected in Ad5-immune mice immunized multiple times with a current generation Ad5 [E1-]-CEA. Ad5 immune mice bearing CEA-expressing tumors that were treated with Ad5 [E1-, E2b-]-CEA had increased anti-tumor response as compared with Ad5 [E1-]-CEA treated mice. These results demonstrate that Ad5 [E1-, E2b-]-CEA can induce CMI immune responses which result in tumor growth inhibition despite the presence of pre-existing Ad5 immunity. Multiple re-immunizations using the same vector platform are now possible with the novel Ad5 [E1-, E2b-] platform.
- Published
- 2010
- Full Text
- View/download PDF
8. Immune modulation associated with extracorporeal immunoadsorption treatments utilizing protein A/silica columns.
- Author
-
Balint JP Jr
- Subjects
- Adjuvants, Immunologic administration & dosage, Adjuvants, Immunologic pharmacology, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid immunology, Biocompatible Materials metabolism, Biocompatible Materials therapeutic use, Blood Platelets cytology, Blood Platelets drug effects, Blood Platelets immunology, Enzyme-Linked Immunosorbent Assay, Humans, Immunoglobulin G metabolism, Immunosorbents pharmacology, Platelet Count drug effects, Purpura, Thrombocytopenic, Idiopathic immunology, Treatment Outcome, Adjuvants, Immunologic therapeutic use, Immunosorbents therapeutic use, Proteins metabolism, Purpura, Thrombocytopenic, Idiopathic therapy, Silicon Dioxide metabolism
- Abstract
The Prosorba column is designed for the removal of IgG and IgG containing immune complexes from plasma. Clinical studies employing patients presenting with idiopathic thrombocytopenic purpura (ITP) indicate that this new form of therapy is effective in approximately 40% of treated patients. Responding patients exhibit a significant increase in platelet numbers associated with decreases in antiplatelet antibody and immune complexes suggesting the induction of immune modulation. Preliminary studies indicate that ITP patients presenting with antiplatelet IgG antibody are those most likely to respond. In addition, this subgroup of ITP patients also exhibit elevated levels of antiidiotypic IgG antibody, which may contribute to an exacerbation of the autoimmune process due to antigen mimicry of the platelet autoantigen. Interestingly, antiidiotypic IgG antibody levels appear to decrease in association with antiplatelet IgG autoantibody levels suggesting that removal of immune complexes composed of IgG autoantibody and platelet autoantigen and/or antiidiotypic IgG antibody may be related to the observed clinical responses. Additional studies with alloimmune patients refractory to platelet transfusion suggest that transfused platelet retention time may be increased as a consequence of immunoadsorption therapy. This clinical response appears to be related to decreases in IgG alloantibody, again suggesting the induction of immune modulation. Alloimmune thrombocytopenic patients also appear to present with elevated levels of antiidiotypic IgG antibody which may contribute to an exacerbation of the alloimmune process due to antigen mimicry of platelet alloantigen(s). Preliminary studies indicate that both IgG alloantibody and corresponding antiidiotypic IgG antibody levels appear to decrease during immunoadsorption therapy, which suggests that removal of these antibodies, possibly in the form of immune complexes, may be related to clinical responses. Finally, studies in rheumatoid arthritis patients suggest that immunoadsorption therapy may be of clinical benefit in this autoimmune disorder. Consistent with the results observed above, preliminary studies in patients responding to immunoadsorption treatments again suggest that there is a concomitant decrease in idiotypic IgG (rheumatoid factor) and antiidiotypic IgG antibodies levels during therapy.
- Published
- 1996
- Full Text
- View/download PDF
9. Modulation of idiotypic and antiidiotypic immunoglobulin G responses in an alloimmune thrombocytopenic patient associated with extracorporeal protein A immunoadsorption.
- Author
-
Balint JP Jr, Hussein MA, Quagliata F, Cochran S, and Jones FR
- Subjects
- Adolescent, Antibodies, Anti-Idiotypic biosynthesis, Antibodies, Anti-Idiotypic immunology, Drug Therapy, Combination, Enzyme-Linked Immunosorbent Assay, Humans, Immunoglobulin G immunology, Immunoglobulin Idiotypes biosynthesis, Immunoglobulin Idiotypes immunology, Immunosorbent Techniques, Isoantibodies immunology, Lymphoma, Non-Hodgkin drug therapy, Male, Pancytopenia chemically induced, Pancytopenia immunology, Pancytopenia therapy, Platelet Transfusion, Thrombocytopenia chemically induced, Thrombocytopenia therapy, Blood Platelets immunology, Immunoglobulin G biosynthesis, Staphylococcal Protein A metabolism, Thrombocytopenia immunology
- Abstract
In the present case study, a patient with Non-Hodgkin. Lymphoma underwent combination chemotherapy resulting in severe pancytopenia requiring transfusion support with blood products. The patient became refractory to random donor platelet transfusions and subsequently received five immunoadsorption treatments. The patient's clinical response to immunoadsorption therapy was assessed by monitoring platelet transfusion recovery and survival. In addition, changes in antibody responses were assessed. Early during the course of immunoadsorption therapy, antiplatelet immunoglobulin G (IgG) alloantibody was detected. There was a decline in antiplatelet IgG alloantibody levels by the last immunoadsorption treatment associated with increases to platelet correct count increments after completion of immunoadsorption therapy. In addition, elevated levels of antiidiotypic IgG antibody detected early during the course of therapy were significantly reduced by the last immunoadsorption treatment. This case study suggests that specific alloimmune idiotypic IgG antibody and corresponding antiidiotypic IgG antibody responses may be modulated in association with extracorporeal immunoadsorption employing protein A/silica columns.
- Published
- 1996
- Full Text
- View/download PDF
10. Association of anti-platelet IgG antibody levels with response to extracorporeal protein A/silica immunoadsorption in ITP patients.
- Author
-
Balint JP Jr, Quagliata F, Cochran SK, and Jones FR
- Subjects
- Humans, Immunosorbent Techniques, Purpura, Thrombocytopenic, Idiopathic immunology, Silicon Dioxide, Staphylococcal Protein A, Blood Platelets immunology, Immunoglobulin G blood, Immunosorbents, Purpura, Thrombocytopenic, Idiopathic therapy
- Published
- 1995
- Full Text
- View/download PDF
11. Evidence for proteolytic cleavage of covalently bound protein A from a silica based extracorporeal immunoadsorbent and lack of relationship to treatment effects.
- Author
-
Balint JP Jr and Jones FR
- Subjects
- Animals, Antigen-Antibody Complex blood, Autoantibodies blood, Autoimmune Diseases blood, Autoimmune Diseases therapy, Chickens blood, Formaldehyde pharmacology, Hemolytic-Uremic Syndrome blood, Hemolytic-Uremic Syndrome therapy, Humans, Immunoglobulin G blood, Immunosuppression Therapy methods, Plasma, Protease Inhibitors pharmacology, Purpura, Thrombocytopenic, Idiopathic blood, Purpura, Thrombocytopenic, Idiopathic therapy, Silicon Dioxide, Staphylococcal Protein A blood, Treatment Outcome, Chromatography, Affinity methods, Endopeptidases blood, Extracorporeal Circulation methods, Immunosorbent Techniques, Staphylococcal Protein A metabolism
- Abstract
Studies were conducted to evaluate the potential cause for release of covalently bound Staphylococcal protein A (SpA) from a silica based extracorporeal immunoadsorbent matrix. In vitro tests revealed that SpA could be detected in human plasma, human serum, and chicken serum upon exposure to the immunoadsorbent matrix which had been treated to remove non-covalently bound SpA. In contrast, only minute quantities of SpA were detected after exposure of a physiologic mixture of purified albumin and immunoglobulin G (IgG) to the immunoadsorbent matrix. Additional tests, employing a cocktail of protease inhibitors and formalin as a general stabilizer and protease inhibitor, revealed significant inhibition of endogenous proteolytic activity present in plasma and serum. Prevention of this proteolytic activity also significantly inhibited the release of covalently bound SpA from the immunoadsorbent matrix upon contact with plasma or serum samples. Further analyses of serum samples from patients with immune thrombocytopenia, chemotherapy associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, and breast cancer revealed a lack of association between the quantity of SpA proteolytically released and observed clinical responses or adverse effects experienced during immunoadsorption treatments. These studies indicate that SpA detected in plasma or serum after exposure to the immunoadsorbent is due to inherent endogenous proteolytic activity which cleaves protein fragments from the matrix and that these cleaved SpA fragments do not appear to contribute to the observed clinical responses or adverse effects in treated patients.
- Published
- 1995
- Full Text
- View/download PDF
12. Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura.
- Author
-
Snyder HW Jr, Cochran SK, Balint JP Jr, Bertram JH, Mittelman A, Guthrie TH Jr, and Jones FR
- Subjects
- Adult, Aged, Aged, 80 and over, Costs and Cost Analysis, Female, Humans, Male, Middle Aged, Prognosis, Purpura, Thrombocytopenic, Idiopathic immunology, Antigen-Antibody Complex isolation & purification, Immunoglobulin G isolation & purification, Immunosorbents metabolism, Purpura, Thrombocytopenic, Idiopathic therapy, Staphylococcal Protein A metabolism
- Abstract
Extracorporeal immunoadsorption of plasma to remove IgG and circulating immune complexes (CIC) was evaluated as a therapy for adults with treatment-resistant immune thrombocytopenic purpura (ITP). Seventy-two patients with initial platelet counts less than 50,000/microL who had failed at least two other therapies were studied. They received an average of six treatments of 0.25 to 2.0 L plasma per procedure over a 2- to 3-week period using columns of staphylococcal protein A-silica (PROSORBA immunoadsorption treatment columns; IMRE Corp, Seattle, WA). The treatments caused an acute increase in the platelet count to greater than 100,000/microL in 18 patients and to 50,000 to 100,000/microL in 15 patients. The median time to response was 2 weeks. Responses were transient (less than 1 month duration) in seven of those patients (10%), but no additional relapses were reported over a follow-up period of up to 26 months (mean of 8 months). Clinical responses were associated with significant decreases in specific serum platelet autoantibodies (including anti-glycoprotein IIb/IIIa), platelet-associated Ig, and CIC. Thirty percent of treatments were associated with transient mild to moderate side effects usually presenting as a hypersensitivity-type reaction. Continued administration of failed therapies for ITP, which always included low-dose corticosteroids (less than or equal to 30 mg/d), had no demonstrable influence on the effectiveness of immunoadsorption treatment but did depress the incidence and severity of side effects. The degree of effectiveness of protein A immunoadsorption therapy in patients with treatment-resistant ITP is promising and further controlled studies in this patient population are warranted.
- Published
- 1992
13. Specificity of antibody responses affected by extracorporeal immunoadsorption of plasma over columns of protein A silica.
- Author
-
Snyder HW Jr, Seawell BW, Cochran SK, Balint JP Jr, and Jones FR
- Subjects
- Adenocarcinoma blood, Adenocarcinoma immunology, Adenocarcinoma therapy, Antibodies, Neoplasm immunology, Antigens, Neoplasm immunology, Autoantibodies immunology, Breast Neoplasms blood, Breast Neoplasms immunology, Breast Neoplasms therapy, Hemolytic-Uremic Syndrome blood, Hemolytic-Uremic Syndrome immunology, Humans, Lewis Blood Group Antigens immunology, Purpura, Thrombocytopenic, Idiopathic blood, Purpura, Thrombocytopenic, Idiopathic immunology, Antibodies, Neoplasm isolation & purification, Antigen-Antibody Complex blood, Autoantibodies isolation & purification, Hemolytic-Uremic Syndrome therapy, Immunosorbent Techniques, Purpura, Thrombocytopenic, Idiopathic therapy, Silicon Dioxide, Staphylococcal Protein A
- Abstract
A relationship is described between the interaction of circulating immune complexes (CIC) from plasma with staphylococcal protein A immunoadsorption treatment columns and modulation of antibody responses related to the specific CIC. Eluates from the initial immunoadsorption columns used to treat a series of patients with breast adenocarcinoma, cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (C-TTP/HUS), or immune thrombocytopenic purpura (ITP) were evaluated for disease-specific CIC containing Lex glycosphingolipid (Lex gl) adenocarcinoma-associated antigens or platelet autoantibody (anti-GPIIb/IIIa), together with the corresponding neutralizing antibody [anti-F(ab')2], and for nonspecific CIC containing cytomegalovirus (CMV) or herpes simplex virus type 1 (HSV-1) antigens. In addition, the levels of antibodies directed against CMV, HSV-1, Lex gl, and GPIIb/IIIa antigens, as well as anti-F(ab')2 antibodies, were compared in pretreatment and posttreatment serum samples. Columns used to treat breast adenocarcinoma patients contained only Lex gl CIC, and the only immunologic change observed after treatment was significant increases in anti-Lex gl antibodies in some patients. Columns used to treat C-TTP/HUS patients contained anti-GPIIb/IIIa-anti-F(ab')2 CIC, in addition to Lex gl CIC. After treatment, significant increases in anti-Lex gl and anti-F(ab')2 antibodies and significant decreases in anti-GPIIb/IIIa antibodies were observed in some patients. Columns used to treat ITP patients only exhibited anti-GPIIb/IIIa-anti-F(ab')2 CIC, and after treatment only decreases in anti-GPIIb/IIIa and increases in anti-F(ab')2 antibodies were observed in some patients.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1992
- Full Text
- View/download PDF
14. Use of protein A immunoadsorption as a treatment for thrombocytopenia in HIV-infected homosexual men: a retrospective evaluation of 37 cases.
- Author
-
Snyder HW Jr, Bertram JH, Henry DH, Kiprov DD, Benny WB, Mittelman A, Messerschmidt GL, Cochran SK, Perkins W, and Balint JP Jr
- Subjects
- Adult, Aged, Blood Platelets immunology, Homosexuality, Humans, Male, Middle Aged, Platelet Count, Retrospective Studies, Thrombocytopenia etiology, Treatment Outcome, Autoantibodies immunology, HIV Infections complications, Immunosorbents pharmacology, Staphylococcal Protein A immunology, Thrombocytopenia drug therapy
- Abstract
Thirty-seven HIV-infected homosexual men with thrombocytopenia (less than 100 x 10(9)/l) received protein A immunoadsorption treatments to remove platelet-sensitizing immunoglobulin (Ig) G and circulating immune complexes (CIC) from plasma. Patients received an average of six treatments each, consisting of 250 ml plasma over a 3-week period. Clinical improvement in hemorrhagic symptoms associated with substantial increase in platelet counts was achieved in 18 patients. These responses were maintained over a median follow-up period of more than 7 months in 14 evaluable patients who were not lost to follow-up (three patients relapsed in 2 weeks and one received another therapy). Generally, moderate transient treatment-related side-effects included fever, musculoskeletal pain, chills and nausea. A transient serum sickness-like reaction was observed in seven patients, leading to termination of treatment in two. Clinical responses were associated with significant decreases in levels of platelet-sensitizing Ig, including CIC. Stimulation of broadly cross-reactive anti-antigen-binding fragment [F(ab)2], antibodies contributed to these responses. Protein A immunoadsorption is an effective alternative treatment for HIV-associated thrombocytopenia.
- Published
- 1991
- Full Text
- View/download PDF
15. Long-term response of immune thrombocytopenia to extracorporeal immunoadsorption.
- Author
-
Balint JP Jr, Snyder HW Jr, Cochran SK, and Jones FR
- Subjects
- Follow-Up Studies, Humans, Immunosorbent Techniques, Autoimmune Diseases therapy, Extracorporeal Circulation, Thrombocytopenia therapy
- Published
- 1991
- Full Text
- View/download PDF
16. Minimal toxicity during protein A immunoadsorption treatment of malignant disease: an outpatient therapy.
- Author
-
Snyder HW Jr, Henry DH, Messerschmidt GL, Mittelman A, Bertram J, Ambinder E, Kiprov D, Balint JP Jr, MacKintosh FR, and Hamburger M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Chromatography, Affinity, Female, Fever etiology, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasms blood, Neoplasms immunology, Antigen-Antibody Complex blood, Blood Component Removal adverse effects, Immunosorbent Techniques adverse effects, Immunosorbents, Neoplasms therapy, Staphylococcal Protein A
- Abstract
Extracorporeal removal or modulation of circulating immune complexes (CIC) from plasma of animals and humans with malignant disease may be associated with induction of immune-mediated anti-tumor responses. Immunoadsorption columns containing heat-killed and formalin-fixed Staphylococcus aureus or staphylococcal protein A have been used for this purpose but treatments have often been associated with cardiopulmonary toxicity. Recently, an immunoadsorption device containing highly purified protein A covalently attached to a silica matrix (PROSORBA column) was used to treat 142 patients with refractory malignancies and 22 of 104 patients evaluated for anti-tumor response had objectively measurable reduction in tumor burden. In contrast to earlier experience with other devices, the procedures used in this trial were well tolerated and could be performed on an outpatient basis. The most common side effects observed among 1,306 treatments were chills (28% of treatments), low grade fever (28%), and musculoskeletal pain (16%). Side effects were mild to moderate and required no treatment or only symptomatic treatment. Treatment schedules were interrupted due to side effects for only six patients and there were no treatment-related deaths. Of 64 patients available for long-term follow-up evaluation (mean of 11 months), none exhibited evidence of long-term treatment-related side effects. None of the patient deaths in that period were associated with short or long-term treatment-related side effects. Protein A-silica (PROSORBA columns) can be used safely for development of further experimental treatments of malignant disease.
- Published
- 1991
- Full Text
- View/download PDF
17. Isolation and purification of murine monoclonal IgG1 employing specific immuno-affinity chromatography.
- Author
-
Balint JP Jr
- Subjects
- Animals, Antibodies, Monoclonal immunology, Ascitic Fluid analysis, Chromatography, Affinity, Electrophoresis, Polyacrylamide Gel, Immunoglobulin G immunology, Immunosorbent Techniques, Mice, Precipitin Tests, Antibodies, Monoclonal isolation & purification, Immunoglobulin G isolation & purification
- Abstract
Studies were performed to determine if murine monoclonal immunoglobulin G1 (IgG1) could be purified from ascites fluid employing specific immuno-affinity chromatography. Murine polyclonal IgG was first removed from the ascites fluid by passage over immobilized protein A at pH 7.0. Analysis of the ascites fluid after this procedure revealed that murine monoclonal IgG1 did not bind to the protein A under the conditions employed. Additional analyses revealed that murine polyclonal IgG bound to and could be eluted from the immobilized protein A. Subsequent passage of the ascites fluid through an immunoadsorbent containing sheep antibody to murine monoclonal IgG1 revealed that the murine monoclonal IgG1 isotype was specifically removed. Analyses of the immunoglobulin eluted from the immuno-affinity matrix revealed the presence of murine monoclonal IgG1 with purities equal to or greater than 95%.
- Published
- 1990
- Full Text
- View/download PDF
18. Isolation of human and canine IgM utilizing protein A affinity chromatography.
- Author
-
Balint JP Jr, Ikeda Y, Nagai T, and Terman DS
- Subjects
- Animals, Centrifugation, Density Gradient, Chromatography, Affinity, Chromatography, Gel, Dogs, Humans, Species Specificity, Staphylococcal Protein A pharmacology, Immunoglobulin M isolation & purification
- Abstract
Human and canine high molecular weight IgM's were isolated employing a system of G-200 column chromatography and passage through a protein A Sepharose 4B column. Polyacrylamide Gel Electrophoresis (PAGE) analysis of the isolated immunoglobulin revealed polypeptides corresponding to mu and light immunoglobulin chains of IgM which were identified immunochemically as IgM. Ultracentrifugation studies revealed that the isolated immunoglobulin co-migrated with 19S IgM markers. This simple and efficient procedure may serve as an alternative to classical isolation procedures of IgM from certain mammalian species.
- Published
- 1981
- Full Text
- View/download PDF
19. Modulation of immunity in patients with autoimmune disease and cancer treated by extracorporeal immunoadsorption with PROSORBA columns.
- Author
-
Snyder HW Jr, Balint JP Jr, and Jones FR
- Subjects
- Adenocarcinoma immunology, Animals, Autoimmune Diseases immunology, Breast Neoplasms immunology, Cats, Humans, Immunosorbent Techniques instrumentation, Leukemia Virus, Feline, Leukemia, Experimental complications, Leukemia, Experimental immunology, Lymphoma, Non-Hodgkin complications, Lymphoma, Non-Hodgkin immunology, Purpura, Thrombocytopenic immunology, Adenocarcinoma therapy, Autoimmune Diseases therapy, Breast Neoplasms therapy, Leukemia, Experimental therapy, Lymphoma, Non-Hodgkin therapy, Purpura, Thrombocytopenic therapy
- Abstract
Extensive animal studies and clinical observations support an immunosuppressive role for certain antibodies and circulating immune complexes (CIC) in malignant and autoimmune diseases. Investigators have attempted to correct or modulate dysfunction by removal of antibodies or CIC from plasma. Extra-corporeal immunoadsorption of plasma over columns containing a silica matrix and covalently attached highly purified staphylococcal protein A (PROSORBA column) is a procedure that specifically removes those plasma components by the interaction of protein A with the Fc region of IgG. The interaction of CIC with the Fc receptor on protein A has three specific results. First, there is direct removal of immunosuppressive CIC from the circulation. Studies of CIC-mediated immunosuppression in experimental systems have shown dose-response relationships over wide ranges of CIC concentrations. Thus, removal of CIC relative to the IgG antibody may be expected to exert some stimulation of the immune system. Second, the complement system is activated. Elevated levels of C3a, C4a, and C5a are observed in patients' circulating plasma after PROSORBA treatment. These levels peak one to three hours post-perfusion and are near normal levels by six hours post-perfusion. These complement components are stimulators of growth and activity of immune cells. In addition, by binding to CIC they stimulate clearance of CIC by the reticuloendothelial system. Thus, treatments may induce removal of more CIC than could be anticipated by the binding capacity of treatment columns. Third, antibody is released from CIC. Interaction of CIC with bound protein A with or without the aid of activated complement components leads to liberation of free antibody. Depending upon other factors, eg, amount of circulating antigen and/or unbound IgG, either free antibody or CIC containing more antibody relative to antigen (or both) may be infused into patients with the posttreatment plasma. Such CIC function as immune stimulators rather than suppressors of immune cell activity. The consequences of the treatments are summarized as follows. Stimulation of immune cellular activity is seen one to three hours posttreatment. During the first one to three treatments, cells of the granulocyte/macrophage series show the greatest increase. During and after treatments 2 to 4, lymphocytes show the greatest increase. At this point, increased blastogenic response to mitogens is observed along with an increase in the T helper/suppressor cell ratio.(ABSTRACT TRUNCATED AT 400 WORDS)
- Published
- 1989
20. Circulating immune complexes in rats with metastasizing or nonmetastasizing mammary tumor.
- Author
-
Yoo TJ, Balint JP Jr, Whiteaker RS, Floyd RA, and Kim U
- Subjects
- Adenocarcinoma chemically induced, Animals, Burkitt Lymphoma immunology, Cell Line, Mammary Neoplasms, Experimental immunology, Methylcholanthrene, Radioimmunoassay, Rats, Rats, Inbred Strains, Adenocarcinoma secondary, Antigen-Antibody Complex analysis, Mammary Neoplasms, Experimental secondary
- Abstract
The dual rat metastatic and nonmetastatic mammary tumor model was characterized by the level of immune complexes in the sera of rats bearing these tumors. Circulating immune complexes (CIC) were measured at various intervals posttumor injection in Wistar-Furth (W/Fu) rats inoculated at 2 months of age with either 1 X 10(6) viable metastasizing (TMT-081) or nonmetastasizing (MT-100) tumor cells into the mammary fat pads. The Raji cell assay was used to measure CIC. No correlation between tumor size and CIC levels in the tumors were observed. While none of the sera from the rats bearing the nonmetastasizing tumors had CIC levels higher than 30 micrograms/ml, a small percentage of the animals bearing the metastasizing tumors had serum CIC levels higher than 30 micrograms/ml. This study suggests no clear difference between the amount of CIC in the sera of animals bearing either metastasizing or nonmetastasizing tumors.
- Published
- 1983
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.